Therapeutic utility of Lung-MAP: ushering into an era of genomic and biomarker-driven clinical trials

被引：0
|
作者：
Zhang, Chenyue [1 ]
Wang, Haiyong [2 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Dept Integrated Therapy, Shanghai, Peoples R China
[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Internal Med Oncol, Jinan, Peoples R China
来源：
SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2021年 / 6卷 / 01期
关键词：
D O I：
10.1038/s41392-021-00557-9
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：3
相关论文
共 31 条
  • [21] Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials
    Robert Montal
    Carmen Andreu-Oller
    Laia Bassaganyas
    Roger Esteban-Fabró
    Sebastián Moran
    Carla Montironi
    Agrin Moeini
    Roser Pinyol
    Judit Peix
    Laia Cabellos
    Augusto Villanueva
    Daniela Sia
    Vincenzo Mazzaferro
    Manel Esteller
    Josep M. Llovet
    British Journal of Cancer, 2019, 121 : 340 - 343
  • [22] Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials
    Montal, Robert
    Andreu-Oller, Carmen
    Bassaganyas, Laia
    Esteban-Fabro, Roger
    Moran, Sebastian
    Montironi, Carla
    Moeini, Agrin
    Pinyo, Roser
    Peix, Judit
    Cabellos, Laia
    Villanueva, Augusto
    Sia, Daniela
    Mazzaferro, Vincenzo
    Esteller, Manel
    Llovet, Josep M.
    BRITISH JOURNAL OF CANCER, 2019, 121 (04) : 340 - 343
  • [23] The role of the pathologist in the design and conducting of biomarker-driven clinical trials in cancer: position paper of the European Society of Pathology
    Matias-Guiu, Xavier
    Raspollini, Maria Rosaria
    Kulka, Janina
    Ryska, Ales
    Dieri, Raed Al
    Schirmacher, Peter
    European Society of Pathology ESP
    VIRCHOWS ARCHIV, 2024, : 207 - 214
  • [24] Biomarker-Driven Phenotyping in Parkinson's Disease: A Translational Missing Link in Disease-Modifying Clinical Trials
    Espay, Alberto J.
    Schwarzschild, Michael A.
    Tanner, Caroline M.
    Fernandez, Hubert H.
    Simon, David K.
    Leverenz, James B.
    Merola, Aristide
    Chen-Plotkin, Alice
    Brundin, Patrik
    Kauffman, Marcelo A.
    Erro, Roberto
    Kieburtz, Karl
    Woo, Daniel
    Macklin, Eric A.
    Standaert, David G.
    Lang, Anthony E.
    MOVEMENT DISORDERS, 2017, 32 (03) : 319 - 324
  • [25] Cancer clinical trials in the era of genomic signatures: Biomedical innovation, clinical utility, and regulatory-scientific hybrids
    Kohli-Laven, Nina
    Bourret, Pascale
    Keating, Peter
    Cambrosio, Alberto
    SOCIAL STUDIES OF SCIENCE, 2011, 41 (04) : 487 - 513
  • [26] Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer
    Park, Sehhoon
    Kim, Yu Jung
    Min, Young Joo
    Mortimer, Peter G. S.
    Kim, Hee-Jung
    Smith, Simon A.
    Dean, Emma
    Jung, Hyun Ae
    Sun, Jong-Mu
    Park, Woong-Yang
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Lee, Se-Hoon
    Park, Keunchil
    CANCER, 2024, 130 (04) : 541 - 552
  • [27] Comprehensive Genomic Profiling of Lung Adenocarcinoma Identifies Patients with Genomic Alterations beyond Clinical Testing Guidelines Who May Benefit from Enrollment in Mechanism Driven Clinical Trials
    Albacker, Lee
    Chmielecki, Juliann
    Elvin, Julia A.
    Vergilio, Jo-Anne
    Miller, Vincent A.
    Stephens, Philip J.
    Ross, Jeffrey S.
    Ali, Siraj M.
    Suh, James
    MODERN PATHOLOGY, 2016, 29 : 451A - 451A
  • [28] Comprehensive Genomic Profiling of Lung Adenocarcinoma Identifies Patients with Genomic Alterations beyond Clinical Testing Guidelines Who May Benefit from Enrollment in Mechanism Driven Clinical Trials
    Albacker, Lee
    Chmielecki, Juliann
    Elvin, Julia A.
    Vergilio, Jo-Anne
    Miller, Vincent A.
    Stephens, Philip J.
    Ross, Jeffrey S.
    Ali, Siraj M.
    Suh, James
    LABORATORY INVESTIGATION, 2016, 96 : 451A - 451A
  • [29] Evaluation of an automated artificial intelligence (AI)/ natural language processing (NLP) engine to match patients (pts) with advanced solid cancers to biomarker-driven early phase (EP) clinical trials.
    Morton, Cienne
    Ruta, Daniel
    Stavraka, Chara
    Anam, Kaiser
    Spicer, James F.
    Regan, Aoife
    Sengul, Siru
    Cernile, George
    Borecki, Yulia
    Schwering, Taralyn
    Rai, Harpreet
    Brierley, Phil
    Duroe, Oenone
    Quarterman, Alan
    Sarker, Debashis
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials
    Suh, James H.
    Johnson, Adrienne
    Albacker, Lee
    Wang, Kai
    Chmielecki, Juliann
    Frampton, Garrett
    Gay, Laurie
    Elvin, Julia A.
    Vergilio, Jo-Anne
    Ali, Siraj
    Miller, Vincent A.
    Stephens, Philip J.
    Ross, Jeffrey S.
    ONCOLOGIST, 2016, 21 (06): : 684 - 691
1234